Alzheimer’s Disease Model
Alzheimer's Disease
ResearchActive
Key Facts
About Neurix
Neurix is a private, Switzerland-based biotech company leveraging human iPSC technology to create advanced 3D in vitro models of the brain for preclinical research. Its core business is providing specialized research services and proprietary model systems, such as its BlastomaBrain™ glioblastoma model, to pharmaceutical and academic partners to improve the predictability of neuroscience drug discovery. The company is led by a team with strong scientific and business backgrounds and has been supported by European research funding. Neurix operates as a pre-revenue platform and services company, focusing on neurodegenerative diseases and neuro-oncology.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |